Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 13


Association of Chromosomal Translocation and MiRNA Expression with The Pathogenesis of Multiple Myeloma.

Saki N, Abroun S, Hajizamani S, Rahim F, Shahjahani M.

Cell J. 2014 Summer;16(2):99-110. Epub 2014 May 25. Review.


Staging and prognostication of multiple myeloma.

Fonseca R, Monge J, Dimopoulos MA.

Expert Rev Hematol. 2014 Feb;7(1):21-31. doi: 10.1586/17474086.2014.882224. Review.


Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma.

Van Wier S, Braggio E, Baker A, Ahmann G, Levy J, Carpten JD, Fonseca R.

Haematologica. 2013 Oct;98(10):1586-92. doi: 10.3324/haematol.2012.081083. Epub 2013 May 28.


Classify hyperdiploidy status of multiple myeloma patients using gene expression profiles.

Li Y, Wang X, Zheng H, Wang C, Minvielle S, Magrangeas F, Avet-Loiseau H, Shah PK, Zhang Y, Munshi NC, Li C.

PLoS One. 2013;8(3):e58809. doi: 10.1371/journal.pone.0058809. Epub 2013 Mar 15.


A phthalimide derivative that inhibits centrosomal clustering is effective on multiple myeloma.

Shiheido H, Terada F, Tabata N, Hayakawa I, Matsumura N, Takashima H, Ogawa Y, Du W, Yamada T, Shoji M, Sugai T, Doi N, Iijima S, Hattori Y, Yanagawa H.

PLoS One. 2012;7(6):e38878. doi: 10.1371/journal.pone.0038878. Epub 2012 Jun 25.


Soluble syndecan-1 at diagnosis and during follow up of multiple myeloma: a single institution study.

Kim JM, Lee JA, Cho IS, Ihm CH.

Korean J Hematol. 2010 Jun;45(2):115-9. doi: 10.5045/kjh.2010.45.2.115. Epub 2010 Jun 30.


Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma.

Chng WJ, Gertz MA, Chung TH, Van Wier S, Keats JJ, Baker A, Bergsagel PL, Carpten J, Fonseca R.

Leukemia. 2010 Apr;24(4):833-42. doi: 10.1038/leu.2010.21. Epub 2010 Mar 11.


Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Greipp PR, Hayman SR, Kyle RA, Lacy MQ, Lust JA, Reeder CB, Roy V, Russell SJ, Short KE, Stewart AK, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Bergsagel PL.

Mayo Clin Proc. 2009 Dec;84(12):1095-110. doi: 10.4065/mcp.2009.0603.


Front-line treatment in younger patients with multiple myeloma.

Rajkumar SV, Sonneveld P.

Semin Hematol. 2009 Apr;46(2):118-26. doi: 10.1053/j.seminhematol.2009.02.005. Review.


Multiple myeloma.

Rajkumar SV.

Curr Probl Cancer. 2009 Jan-Feb;33(1):7-64. doi: 10.1016/j.currproblcancer.2009.01.001. Review. No abstract available.


Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma.

Kyle RA, Rajkumar SV.

Leukemia. 2009 Jan;23(1):3-9. doi: 10.1038/leu.2008.291. Epub 2008 Oct 30. Review. Erratum in: Leukemia. 2014 Apr;28(4):980.


Genetic events in the pathogenesis of multiple myeloma.

Chng WJ, Glebov O, Bergsagel PL, Kuehl WM.

Best Pract Res Clin Haematol. 2007 Dec;20(4):571-96. Review.


Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.

Georges GE, Maris MB, Maloney DG, Sandmaier BM, Sorror ML, Shizuru JA, Lange T, Agura ED, Bruno B, McSweeney PA, Pulsipher MA, Chauncey TR, Mielcarek M, Storer BE, Storb R.

Biol Blood Marrow Transplant. 2007 Apr;13(4):423-32. Epub 2007 Feb 1.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk